GlassScriptPhysician profile
Katie E Barnes
NPI 1023046794
$6,768.31
in general payments reported to CMS, 2019-2025
32 companies · $1,347 in 2025
The $1,347 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,107 · 2022: $1,581 · 2023: $1,405 · 2024: $1,329 · 2025: $1,347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,081.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,035.57 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $887.79 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $748.28 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $550.81 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Biohaven Pharmaceutical Holding Company LTD. | $486.72 | 2022 | |
| Pfizer INC. | $282.47 | 2021-2025 | |
| Glaxosmithkline, LLC. | $278.92 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $236.51 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $185.25 | 2023-2025 | Gvoke Hypopen |
| Abbott Laboratories | $153.70 | 2022-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $129.57 | 2023-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $127.01 | 2023-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.53 | 2023-2025 | Jardiance, Synjardy |
| Otsuka America Pharmaceutical, INC. | $85.18 | 2022-2025 | Rexulti |
| Amgen INC. | $77.51 | 2021-2025 | Repatha, Otezla, Otezla |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $50.53 | 2023-2024 | Accrufer |
| Stryker Corporation | $48.75 | 2024 | 7 X 23mm Citrelock Implant, Citrefix, Anchorage |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.42 | 2025 | Caplyta |
| Alnylam Pharmaceuticals INC. | $27.45 | 2025 | Givlaari |
| Alexion Pharmaceuticals, INC. | $26.30 | 2021 | |
| Harmony Biosciences LLC | $23.63 | 2025 | |
| Agios Pharmaceuticals, INC. | $23.61 | 2025 | Pyrukynd |
| Insulet Corporation | $20.39 | 2023 | Omnipod |
| Daiichi Sankyo INC. | $18.92 | 2022 | |
| Axsome Therapeutics, INC. | $16.50 | 2023 | Auvelity |
| Tersera Therapeutics LLC | $15.19 | 2024 | Zoladex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.96 | 2021 | |
| Astellas Pharma US INC | $14.16 | 2024 | Veozah |
| Currax Pharmaceuticals LLC | $14.00 | 2023 | Nexlizet, Nexletol, Contrave |
| Kiniksa Pharmaceuticals, LTD. | $13.91 | 2022 | |
| Idorsia Pharmaceuticals US INC | $12.63 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $12.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.